{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.90","value":"3.8"},{"groupId":"OG001","spread":"6.36","value":"5.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"179"}],"units":"Participants"}],"description":"RBC transfusion burden on treatment is defined as total number of packed red blood cell (pRBC) units transfused within the first 24 weeks of treatment since Week 1.","dispersionType":"Standard Deviation","groups":[{"description":"Starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (21 days; Q3W). Dose levels can be increased in a stepwise manner beyond the starting dose to 1.33 mg/kg, and up to a maximum of 1.75 mg/kg.","id":"OG000","title":"Luspatercept"},{"description":"Starting dose of 450 IU/kg (maximum total starting dose is 40,000 IU) subcutaneous injection once every week (7 days; QW). Dose levels can be increased in a stepwise manner beyond the starting dose to 787.5 IU/kg, and up to a maximum of 1,050 IU/kg (with a maximum total dose of 80,000 IU).","id":"OG001","title":"Epoetin Alfa"}],"paramType":"MEAN","populationDescription":"All participants who were randomized and received at least one dose.","reportingStatus":"POSTED","timeFrame":"Week 1 through Week 24","title":"The Number of Red Blood Cell (RBC) Units Transfused Within the First 24 Weeks of Treatment","type":"SECONDARY","unitOfMeasure":"RBC units"}